Quantcast

Latest Breast cancer treatment Stories

2014-06-06 23:05:52

Patients with a particularly stubborn type of breast cancer could potentially benefit by supplementing radiation treatments with a generic, low-cost medication commonly prescribed to treat high cholesterol, according to a new study released today in Stem Cells Translational Medicine. Durham, NC (PRWEB) June 06, 2014 Patients with a particularly stubborn type of breast cancer could potentially benefit by supplementing radiation treatments with a generic, low-cost medication commonly...

2014-06-04 15:29:19

Albert Einstein College of Medicine The study was led by researchers at the National Cancer Institute (NCI)─designated Albert Einstein Cancer Center of Albert Einstein College of Medicine of Yeshiva University and Montefiore Einstein Center for Cancer Care and was published online today in the Journal of the National Cancer Institute (JNCI). "Tests assessing metastatic risk can help doctors identify which patients should receive aggressive therapy and which patients should be spared,"...

2014-06-04 11:26:06

American Heart Association Study Highlights: -About 12 percent of older breast cancer patients developed heart failure within three years, often as a result of the cancer drugs and treatments. -Only a third of older breast cancer patients saw a cardiologist within 90 days of developing heart problems. -Those who saw a cardiologist were more likely to receive standard drugs for heart failure than those who didn’t. Only a third of older breast cancer patients saw a cardiologist...

2014-06-03 15:54:17

Rice University Animal tests show Rice-developed technology effective against aggressive cancer The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells -- often by blowing them apart -- without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports that Rice's "quadrapeutics" technology...

2014-06-03 11:21:00

University of Texas M. D. Anderson Cancer Center Early but promising results lead to Phase II national trial In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. The Phase I trial, presented Saturday, May 31 in a poster discussion at the American Society of Clinical Oncology's...

2014-06-02 16:26:24

OAKLAND, Calif., June 2, 2014 /PRNewswire/ -- Patients with specific HER2+ breast cancer tumors have a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published in the Journal of Clinical Oncology. http://photos.prnewswire.com/prnvar/20130718/SF49717LOGO Researchers reviewed 16,975 cases of breast cancer diagnosed in Kaiser Permanente patients between 2000 and 2006....

2014-06-02 08:31:43

Results indicate that it's possible for breast cancer patients to receive adequate doses of radiation therapy while undergoing patient-controlled tissue expansion as part of the breast reconstruction process PALO ALTO, Calif., June 2, 2014 /PRNewswire/ -- AirXpanders Inc., a company developing novel technology for women who require tissue expansion for breast reconstruction following a mastectomy, today reported published results that show that acceptable levels of radiation can be...

2014-05-29 08:29:37

New Data Presented at ASCO® Annual Meeting Suggest that Genomic Health's Oncotype DX Test May Help Identify Patients That Have the Greatest Opportunity to Benefit from Extended Hormonal Therapy REDWOOD CITY, Calif., May 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of a large, positive study that confirmed that the Oncotype DX® test results for Recurrence Score® and quantitative estrogen-receptor (ER) predict late distant recurrence risk in...

2014-05-27 08:29:27

Initial Responses Seen Before Patients Have Completed Treatments; BETHESDA, Md., May 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a summary of initial data to date in its ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors. The Company reported that over 50% of the patients who have completed at least half of...

2014-05-20 23:09:02

Funds will expand commercialization of market-leading early-stage breast cancer treatment. (PRWEB) May 20, 2014 ALISO VIEJO, Calif: Cianna Medical, Inc., a women’s health company, today announced it has secured a $10 million financing deal with GE Capital’s Healthcare Financial Services business. The funds will be used to further product development efforts in the breast conservation therapy (BCT) market, as well as expand the commercialization of the company’s SAVI® breast...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'